Coastlands Capital LP has disclosed a major ownership stake in Bolt Biotherapeutics, Inc., as detailed in a recent SEC filing. This development is notable as it reflects Coastlands' growing influence within the pharmaceutical preparations sector.

According to the filing, Coastlands Capital LP, which is based in San Francisco, California, has reported ownership of 412,416 shares of common stock in Bolt Biotherapeutics. Additionally, Coastlands holds 1,166,275 shares of Series D Non-Voting Convertible Preferred Stock and 583,138 warrants to purchase common stock. This substantial ownership position may signal a strategic investment aimed at influencing Bolt’s future direction.

The filing, accession number 0001104659-26-124005, was submitted on November 6, 2026, under Form 3, which is used to report ownership changes by major shareholders. Coastlands Capital LP is identified as a ten percent owner of Bolt Biotherapeutics, which has implications for its role in the company’s governance and strategic decisions.

Background

Coastlands Capital LP is a limited partnership incorporated in Delaware. It operates as an investment adviser and is actively involved in managing investments in various sectors, including life sciences. Bolt Biotherapeutics, Inc., the issuer of the securities, is categorized under the pharmaceutical preparations sector, specifically focusing on innovative therapies.

What the Filing Says

The filing indicates that Coastlands Capital LP has a direct ownership of 412,416 shares of common stock and holds convertible preferred stock and warrants that could significantly increase its stake in Bolt Biotherapeutics. The document notes, "Coastlands may not convert such shares if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion." This limitation reflects regulatory considerations surrounding ownership thresholds.

Impact

This ownership change may affect various stakeholders, including existing shareholders of Bolt Biotherapeutics, who may view Coastlands' involvement as a positive signal of confidence in the company’s prospects. Additionally, competitors in the pharmaceutical preparations sector may need to reassess their strategies in light of Coastlands' increased stake and potential influence over Bolt’s strategic decisions.

What's Next

The filing does not specify what actions Coastlands Capital LP plans to take following this disclosure. However, the significant ownership stake may lead to further filings or strategic moves as Coastlands seeks to leverage its influence within Bolt Biotherapeutics.